NASDAQ : BNR
Burning Rock Biotech Limited — Key statistics
Healthcare · Diagnostics & Research · China
Last price 10.9 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 114.96M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 110.31M |
| Enterprise Value | 55.59M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 19, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 10.55M |
| Shares Change (YoY) | +0.43% |
| Shares Change (QoQ) | +3.24% |
| Owned by Insiders (%) | 30.92% |
| Owned by Institutions (%) | 10.71% |
| Float | 3.32M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.56 |
| Forward PS | n/a |
| PB Ratio | 1.62 |
| P/TBV Ratio | 1.57 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 0.82 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.05 |
| Quick Ratio | 2.76 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,083.57 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -12.82% |
| Return on Assets (ROA) | -5.16% |
| Return on Invested Capital (ROIC) | -7.09% |
| Return on Capital Employed (ROCE) | -12.20% |
| Weighted Average Cost of Capital (WACC) | 10.75% |
| Revenue Per Employee | $110,497 |
| Profits Per Employee | -$15,014 |
| Employee Count | 667 |
| Asset Turnover | 0.64 |
| Inventory Turnover | 2.77 |
Taxes
| Measure | Value |
|---|
| Income Tax | 236,574 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.29 |
| 52-Week Price Change | -24.29% |
| 50-Day Moving Average | 13.25 |
| 200-Day Moving Average | 16.38 |
| Relative Strength Index (RSI) | 35.57 |
| Average Volume (20 Days) | 23,274 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 36,898 |
| Short Previous Month | 41,425 |
| Short % of Shares Out | 0.52% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.13 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 73.70M |
| Gross Profit | 54.95M |
| Operating Income | -9.57M |
| Pretax Income | -9.78M |
| Net Income | -10.01M |
| EBITDA | -8.58M |
| EBIT | -9.57M |
| Loss Per Share | -$0.95 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 61.36M |
| Total Debt | 6.64M |
| Net Cash | 54.72M |
| Net Cash Per Share | $5.19 |
| Equity (Book Value) | 73.18M |
| Book Value Per Share | 6.74 |
| Working Capital | 65.73M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -1.84M |
| Capital Expenditures | -789,240 |
| Depreciation & Amortization | 1.01M |
| Net Borrowing | 285,684 |
| Free Cash Flow | -2.63M |
| FCF Per Share | -$0.25 |
Margins
| Measure | Value |
|---|
| Gross Margin | 74.55% |
| Operating Margin | -12.99% |
| Pretax Margin | -13.27% |
| Profit Margin | -13.59% |
| EBITDA Margin | -11.64% |
| EBIT Margin | -12.99% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.43% |
| Shareholder Yield | -0.43% |
| Earnings Yield | -9.04% |
| FCF Yield | -2.29% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 38.13% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | May 15, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -4.18 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |